KCT0004300
Completed
未知
A 8-week, multi-center, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Hwangchil-unripe Bokbunja Extract Mixtures on blood pressure
Wonkwang University Oriental Medical Hospital, Jeonju0 sites88 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Wonkwang University Oriental Medical Hospital, Jeonju
- Enrollment
- 88
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\)Males and females aged 19\-75 years at the screening examination
- •2\)Participants who have no history to treat for hypertension within the last 3 months and with 120\=systolic blood pressure(SBP)\=139 or 80\=diastolic blood pressure(DBP)\=89
- •3\)Participants who have fully understand the information provided about the study voluntarily decided to participate and agree to comply with precautions
Exclusion Criteria
- •1\)Patients with 160\=systolic blood pressure(SBP) or 100\=diastolic blood pressure(DBP)
- •2\)Patients with severe diseases for clinically significant
- •(i.e., Heart failure, myocardial infarction, cerebrovascular disease, arteriosclerosis, diabetes mellitus, thyroid disease, gastric ulcer, gastric bleeding, infectious disease, systemic inflammatory disease, acute inflammation, malignant tumor, kidney disease, renal dysfunction, liver disease, hypertensive retinopathy, Crohn’s disease, etc.)
- •3\)Patients who took drugs for hypertension within the last 3 months
- •4\)Patients with a history of antipsychotic medication use within 2 months prior to the screening examination
- •5\)Patients with a history of medicine or alcohol abuse
- •6\)Patients who have participated in other clinical trials within 2 months prior to the screening examination
- •7\)Patients who the following results in a laboratory test
- •? Aspartate Transaminase(AST), Alanine Transaminase(ALT) \> Reference range 3 times upper limit
- •? Serum Creatinine \> 2\.0 mg/dL
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
An 8-week, multi-center, randomized, double-blind, placebo-controlled, parallel group trial of Diclofenac Sodium Gel 1% in patients with primary osteoarthritis of the hand - N/APrimary osteoarthritis of the hand.MedDRA version: 7.1Level: LLTClassification code 10058192EUCTR2004-004776-37-DEovartis Consumer Health S.A.360
Active, not recruiting
Not Applicable
An 8-week, multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in patients with moderate to severe hypertensioEUCTR2006-000774-70-GBovartis Pharma Services AG2,252
Active, not recruiting
Not Applicable
An 8-week, multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in patients with moderate to severe hypertensioEUCTR2006-000774-70-SEovartis Pharma Services AG2,252
Active, not recruiting
Not Applicable
An 8-week, multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in patients with moderate to severe hypertensioHypertensionEUCTR2006-000774-70-GRovartis Pharma Services AG2,252
Active, not recruiting
Phase 1
An 8-week, multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in patients with moderate to severe hypertensioEUCTR2006-000774-70-DKovartis Pharma Services AG2,252